Good morning :)
$
₹
Denali Therapeutics Inc

Denali Therapeutics Inc

DNLI

NASDAQ
Asset Logo

Denali Therapeutics Inc

DNLI

NASDAQ
$18.550.79% (+0.14)
$
₹
$18.550.79% (+0.14)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $2.9B the stock is ranked 1857

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

4.06
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.84
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 20 analysts reports

Buy
19 analysts
Hold
1 analyst
Sell
0 analyst

Price Upside

+92.83%

Earnings Growth

+24.97%

Rev. Growth

—

See Detailed Forecast

Company Profile

Company Profile

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
80.68
80.68
1Y Return
24.94%
24.94%
Buy Reco %
80.00
80.00
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.28
27.28
1Y Return
51.04%
51.04%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
29.23%
29.23%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
29.90
29.90
1Y Return
23.96%
23.96%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
662.28%
662.28%
Buy Reco %
21.73
21.73
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 92.83% growth, versus a trailing 3-year CAGR of -0.52%.

2026
Current$18.41Baseline
Analyst Target - 1 year
Target$35.5+92.83%

All values in $

202220232024202520262027$20.91$26.95$33.00Target+92.83%
2026
Current$18.41Baseline
Analyst Target - 1 year
Target$35.5+92.83%

All values in $

Revenue Forecast

Revenue Forecast

2025
Current$0Baseline
Forecast for Dec 2026
High$262.22
Average$50.65
Low$21.9

All values in $ Million

20212022202320242025202648.66108.46330.5300LowAverageHigh
2025
Current$0Baseline
Forecast for Dec 2026
High$262.22
Average$50.65
Low$21.9

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-2.97Baseline
Forecast for Dec 2026
High$-0.22+92.59%
Average$-2.23+24.97%
Low$-2.75+7.37%

All values in $

202120222023202420252026-2.39-2.6-1.08-2.67-2.97Low+7.37%Average+24.97%High+92.59%
2025
Current$-2.97Baseline
Forecast for Dec 2026
High$-0.22+92.59%
Average$-2.23+24.97%
Low$-2.75+7.37%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

-126.9
-128.5
-128.4
3.6
-127.5
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue0000000003.60
Net Income-101.80-99.02-107.19-114.75-132.97-124.11-126.90-128.54-128.44-127.55
Net Profit Margin----------3539.20%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Denali Therapeutics Inc -4.06-
AbbVie Inc80.6850.450.53
Amgen Inc27.2817.562.28
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare DNLI with any stock or ETF
Compare DNLI with any stock or ETF
Comparing from
DNLI
ABBV
AMGN
Loading...

Frequently asked questions

  1. Denali Therapeutics Inc (DNLI) share price today is $18.55 as of October 27, 2026 at 12:15 AM IST. The stock touched a day high of $18.66 and a day low of $18.27.

  2. Denali Therapeutics Inc stock trades on NASDAQ under the ticker symbol DNLI.

  3. Denali Therapeutics Inc's market capitalization is $2.94B as of October 27, 2026 at 12:15 AM IST.

  4. Denali Therapeutics Inc's price-to-earnings (P/E) ratio is N/A as of October 26, 2026.

  5. Denali Therapeutics Inc's price-to-book (P/B) ratio is 4.06 as of October 26, 2026.

  6. Yes, You can buy Denali Therapeutics Inc shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Denali Therapeutics Inc shares in three steps: 1. Search Denali Therapeutics Inc on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Denali Therapeutics Inc trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Denali Therapeutics Inc (DNLI) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.5389 shares at the current price of $18.55.

Loading...